Pharmacokinetics and pharmacodynamics in the development of anti-tuberculosis drugs.
about
Translating basic science insight into public health action for multidrug- and extensively drug-resistant tuberculosisDetermination of [11C]rifampin pharmacokinetics within Mycobacterium tuberculosis-infected mice by using dynamic positron emission tomography bioimaging.The Role of Adherence and Retreatment in De Novo Emergence of MDR-TBTherapeutic drug monitoring for slow response to tuberculosis treatment in a state control program, Virginia, USA.Fast standardized therapeutic-efficacy assay for drug discovery against tuberculosis.Comparative studies evaluating mouse models used for efficacy testing of experimental drugs against Mycobacterium tuberculosis.Pharmacokinetics and pharmacodynamics of TMC207 and its N-desmethyl metabolite in a murine model of tuberculosis.Evaluation of high-dose rifampin in patients with new, smear-positive tuberculosis (HIRIF): study protocol for a randomized controlled trial.A time-to-event pharmacodynamic model describing treatment response in patients with pulmonary tuberculosis using days to positivity in automated liquid mycobacterial cultureUltra-short-course chemotherapy for spinal tuberculosis: five years of observation.Antituberculosis drugs: drug interactions, adverse effects, and use in special situations. Part 2: second line drugs.Therapeutic drug monitoring in the treatment of tuberculosis: an update.Pharmacologic considerations in use and development of antituberculosis drugs.Antituberculosis drugs in children.Comprehensive physicochemical, pharmacokinetic and activity profiling of anti-TB agents.Forecasting Accuracy of the Hollow Fiber Model of Tuberculosis for Clinical Therapeutic Outcomes.Reduced Chance of Hearing Loss Associated with Therapeutic Drug Monitoring of Aminoglycosides in the Treatment of Multidrug-Resistant TuberculosisLeishmania and other intracellular pathogens: selectivity, drug distribution and PK-PD.Microbial protein targets: towards understanding and intervention.Hit Generation in TB Drug Discovery: From Genome to Granuloma.Assessment methods of inhaled aerosols: technical aspects and applications.Pharmacokinetics of rifampicin in adult TB patients and healthy volunteers: a systematic review and meta-analysis.Improving rifamycin production in by expressing a hemoglobin () gene fused to a cytochrome P450 monooxygenase domain
P2860
Q26824812-27DFAC5F-0EB0-4057-BA9A-018F9FBBAEE5Q27324299-98E744BA-AB15-45C4-9F51-DF035C3EC2F4Q28550707-DBBA5053-0104-4A33-A326-8D241EC9BC0CQ30427912-D28E8095-6B42-4AD9-8BA7-3DD5B9818D37Q33826465-A3D916F8-2F51-4D08-B4EF-96849D333E84Q34737143-C417B8BF-93B4-4FE4-878C-04B56B711F0CQ35806445-764E688D-C103-4A67-B498-DCF5683B6F50Q36115081-71312B89-9F27-416C-90F7-1BD6E9FD8268Q36558478-842E60A3-A304-4803-AE1D-1F7EB5F40810Q36564239-E3BC9FD4-614B-4440-9DB6-24FEA18676D5Q37810481-B358922D-9DF0-4141-9138-21C1C450DDFFQ38213320-B483035E-22B6-49E1-BF6D-F2F16A9BAF40Q38252559-CC6AEA90-7325-4162-B293-EC6B24D63EEFQ38533435-3D908758-FA03-485F-8FAB-812F14A164C9Q38920104-B7ABA594-E1BD-43A3-B415-595FB48AAE3DQ38979626-983D2BAC-3459-4689-BE97-1D01FB47CB85Q39030684-9F2C618E-6E6F-48F5-9869-9C72F4916009Q41990715-33760480-305A-4244-B38F-1AD0CA579E0EQ47215889-C03CD4FB-AB7E-41AA-AF22-07310199D83BQ47702665-2548E0C4-E233-479E-A448-3B6956C0CB72Q51808165-1B6D1AF2-9672-4F8F-8105-5FDA990DBE4AQ52559111-9E49A1F9-4762-477C-839C-D2FF60D104BDQ58077293-3DE9B7AD-8B25-45DC-8FAD-3C6C305D39A7
P2860
Pharmacokinetics and pharmacodynamics in the development of anti-tuberculosis drugs.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on August 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Pharmacokinetics and pharmacodynamics in the development of anti-tuberculosis drugs.
@en
Pharmacokinetics and pharmacodynamics in the development of anti-tuberculosis drugs.
@nl
type
label
Pharmacokinetics and pharmacodynamics in the development of anti-tuberculosis drugs.
@en
Pharmacokinetics and pharmacodynamics in the development of anti-tuberculosis drugs.
@nl
prefLabel
Pharmacokinetics and pharmacodynamics in the development of anti-tuberculosis drugs.
@en
Pharmacokinetics and pharmacodynamics in the development of anti-tuberculosis drugs.
@nl
P1433
P1476
Pharmacokinetics and pharmacodynamics in the development of anti-tuberculosis drugs.
@en
P2093
E L Nuermberger
G R Davies
P304
P356
10.1016/S1472-9792(08)70037-4
P478
88 Suppl 1
P577
2008-08-01T00:00:00Z